Patterns of care of breast cancer patients in Morocco – A study of variations in patient profile, tumour characteristics and standard of care over a decade

Mrabti, Hind; Sauvaget, Catherine; Benider, Abdellatif; Bendahhou, Karima; Selmouni, Farida; Muwonge, Richard; Alaoui, Leila; Lucas, Eric; Chami, Youssef; Villain, Patricia; Abousselham, Loubna; Carvalho, André Lopes; Bennani, Maria; Errihani, Hassan; Sankaranarayanan, Rengaswamy; Bekkali, Rachid; Basu, Partha

doi:10.1016/j.breast.2021.07.009

Cited by 10 publications

(12 citation statements)

References 26 publications

(28 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In Northern Africa, Morocco has made significant investments in improving breast cancer detection and treatment [26] , [27] in the last years; however, our data from the Rabat registry indicate that breast cancer stage distribution has not shifted when compared to previously reported 2006–2008 data [28] . For Casablanca, a transition to use TNM replacing former use of SEER [29] impedes assessing changes in breast cancer stage; however, hospital-based studies at one major Casablanca institution in 2004, 2009 and 2018 report increasing diagnosis of early-stage breast cancer over time [30] , [31] .…”

Section: Discussioncontrasting

confidence: 54%

Staging practices and breast cancer stage among population-based registries in the MENA region

Piñeros

Ginsburg

Bendahhou

et al. 2022

Cancer Epidemiology

Self Cite

View full text Add to dashboard Cite

Section: Discussioncontrasting

confidence: 54%

Staging practices and breast cancer stage among population-based registries in the MENA region

Piñeros

Ginsburg

Bendahhou

et al. 2022

Cancer Epidemiology

Self Cite

View full text Add to dashboard Cite

“…Data reported in Moroccan population, showed a higher proportion of BC among young women aged between 45 to 49 years, and a frequent clinical observation of family history. All this suggests a strong influence of high-penetrance genetic factors in BC etiology [ 14 , 15 ].…”

Section: Introductionmentioning

confidence: 99%

Increased prevalence of the founder BRCA1 c.5309G>T and recurrent BRCA2 c.1310_1313delAAGA mutations in breast cancer families from Northerstern region of Morocco: evidence of geographical specificity and high relevance for genetic counseling

Melki

Melloul

Aissaoui³

et al. 2023

BMC Cancer

View full text Add to dashboard Cite

Background Inherited mutations in the breast cancer susceptibility genes BRCA1 and BRCA2 (BRCA1/2) confer high risks of breast and ovarian cancer. Because the contribution of BRCA1/2 germline mutations to BC in the Northeastern population of Morocco remains largely unknown, we conducted this first study to evaluate the prevalence and the phenotypic spectrum of two BRCA1/2 pathogenic mutations (the founder BRCA1 c.5309G>T and BRCA2 c.1310_1313delAAGA). This choice was also argued by the presence of an apparent specific geographical connection of these mutations and the Northeastern region of Morocco. Methods Screening for the germline mutations c.5309G>T and BRCA2 c.1310_1313delAAGA was performed by sequencing on a total of 184 breast cancer (BC) patients originated from the Northeastern region of Morocco. The likelihood of identifying a BRCA mutation is calculated using the Eisinger scoring model. The clinical and pathologic features were compared between the BRCA-positive and BRCA-negative groups of patients. Difference in survival outcomes was compared between mutation carriers and non-carriers. Results BRCA1 c.5309G>T and BRCA2 c.1310_1313delAAGA are responsible for a significant proportion of all BC cases (12.5%) and at least 20% of familial BC. The screening of BRCA1/2 genes by NGS sequencing confirmed that there are no additional mutations detected among positive patients. The clinicopathological features in positive patients were in accordance with typical characteristics of BRCA pathogenic mutations. The mean features in the carriers were the early onset of the disease, familial history, triple negative status (for BRCA1 c.5309G>T) and worse prognosis in terms of overall surviving. Our study indicates that the Eisinger scoring model could be recommended to identify patients for referral to BRCA1/2 oncogenetic counseling. Conclusion Our findings suggest that BRCA1 c.5309G>T and BRCA2 c.1310_1313delAAGA mutations may have a strong founder and/or recurrent effect on breast cancer among the Northeastern Moroccan population. There contribution to breast cancer incidence is certainly substantial in this subgroup. Therefore, we believe that BRCA1 c.5309G>T and BRCA2 c.1310_1313delAAGA mutations have to be included in the array of tests aimed at revealing cancer syndrome carriers among subjects of Moroccan origin.

show abstract

“…Accounting for 20% of cases. Breast cancer was the most common disease among Moroccan women in 2016, according to a research issued by the Greater Casablanca Cancer Registry of Morocco, accounting for 35.8% of all new malignancies among women [4].…”

Section: Introductionmentioning

confidence: 99%

A mathematical model of Breast cancer (ER+) with excess estrogen: Mixed treatments using Ketogenic diet, endocrine therapy and Immunotherapy

Akil¹,

Fatmi²

2022

Preprint

View full text Add to dashboard Cite

Breast Cancer is a major public health problem and the most common diagnosed malignancy in woman. There have been significant developments in clinical approaches and theoretical experimental to understand the interactions of cancer cells dynamics with the immune system, also developments on analytical and computational models to help provide insights into clinical observations for a better understanding of cancer cells, but more are needed, especially at the genetic and molecular levels mathematically. Treatments such as immunotherapy, chemotherapy, hormone therapy, radiotherapy, and gene therapy are the main strategies in the fight against breast cancer. The present study aims at investigating the effects of estrogen derived from recent models, but this time combined with immunotherapy as a way to treat or inhibit the cancer growth by a mathematical model of breast cancer in situ, governed by a simplified model of nonlinear-coupled ordinary differential equations, that combines important interactions between natural cells, tumor cells, immune cells, ketogenic diet in the presence of an anticancer drug. Another contribution was to introduce the inhibition effect ǫ for new results and conclusions, A qualitative study was performed and biological interpretations were included to understand the conditions of stability in a realistic way.

show abstract

Patterns of care of breast cancer patients in Morocco – A study of variations in patient profile, tumour characteristics and standard of care over a decade

Cited by 10 publications

References 26 publications

Staging practices and breast cancer stage among population-based registries in the MENA region

Staging practices and breast cancer stage among population-based registries in the MENA region

Increased prevalence of the founder BRCA1 c.5309G>T and recurrent BRCA2 c.1310_1313delAAGA mutations in breast cancer families from Northerstern region of Morocco: evidence of geographical specificity and high relevance for genetic counseling

A mathematical model of Breast cancer (ER+) with excess estrogen: Mixed treatments using Ketogenic diet, endocrine therapy and Immunotherapy

Contact Info

Product

Resources

About